A pinch of salt - A podcast by ERA

For decades, treating IgA nephropathy meant looking thoughtful while saying "let's optimise supportive care and monitor closely." Not anymore. We've gone from one road to a full therapeutic roundabout, and nobody wants the wrong exit. Hugo Diniz welcomes Vlado Perkovic to navigate the new era: anti-APRIL and anti-BAFF agents, the VISIONARY and ORIGIN data, and the 2025 KDIGO framework. Are we finally switching off the disease at its source, or just admiring another elegant proteinuria curve? ...

This is “A pinch of salt” live from the 63rd ERA Congress! Recorded straight out of a packed Clyde Plenary Room: six trials, ninety minutes! Hugo Diniz, the new podcast host, brings you rapid-fire expert commentary with two titans of European nephrology, Alberto Ortiz and Danilo Fliser. On the menu — a brand-new CKD drug class (nurandociguat), what patients actually feel on semaglutide (FLOW sub-analysis), two IgA nephropathy therapies going long-term (atrasentan and iptacopan), anticoagulati...

Join A pinch of salt, as we sit down with David Jayne to trace the rapid transformation of ANCA-associated vasculitis care. From the historic cyclophosphamide–glucocorticoid backbone to biologics like rituximab and newer targeted strategies such as complement inhibition (including avacopan), this episode unpacks how clinicians can balance efficacy, safety, and quality of life—while looking ahead to what may define the next decade of treatment.

In this episode of A pinch of salt, Allon N. Friedman will talk about possibly the hottest topic in medicine at this moment – the treatment of obesity, with a particular focus on treating the CKD population. Obesity is finally being recognized as a disease and not merely an unfortunate, somewhat shameful consequence of personalities with weak minds and lack of willpower. But how do we treat it? Does changing lifestyle have any impact, should everybody start taking weight lowering medications,...

In this episode of A pinch of salt, Beatriz Sanchez Alamo will talk about tubulointerstitial nephritis (TIN), the Cinderella of nephrology, a beautiful and interesting topic that is not easily noticeable in congresses and webinars. Some recent data looking at long-term prognosis has shown that patients with TIN might have a long-term prognosis that is comparable to lupus nephritis and ANCA vasculitis. Are we ignoring TIN and if so, what should we be doing differently? In this episode we’ll be...

In this episode we will be talking to Giovanni Tripepi, an expert in biostatistics. Medicine is not just an art but also a science grounded in biostatistics, which is why it is crucial to understand it in order to conduct and interpret research properly. In this episode you will hear about the most common mistakes made by medical researchers when planning a project, the most common mistakes when interpreting data, why a p-value below 0.05 is not always significant and a whole lot more. By the...